Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization

Ravi Murthy*, Paresh Kamat, Rodolfo Nunez, David C. Madoff, Sanjay Gupta, Riad Salem, James C. Yao

*Corresponding author for this work

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Hepatic artery radioembolization was performed in a cohort of patients with unresectable neuroendocrine hepatic metastases who exhibited hepatic progression or toxicity despite technically adequate embolization procedures without other reasonable therapeutic options. Eight patients (five men) with a median age of 55.5 years met the study criteria. Infusions of yttrium-90 resin microspheres were performed in a lobar fashion. Standard clinical, laboratory, and imaging follow-up was performed. Median hepatic parenchyma replacement by tumor was 55% (range, 25%-60%). Twelve 90Y resin microsphere infusions were performed, and the median delivered activity was 33.25 mCi (range, 23-55 mCi). One partial response, four cases of disease stabilization, and three cases of progressive disease were noted. No cases of radiation-induced liver disease occurred. Median survival times were 14 months (range, 3-15 months) from the time of 90Y microsphere treatment and 36.5 months (range, 16-105 months) from the time of diagnosis of hepatic metastases. In this cohort, 90Y microsphere radioembolization of neuroendocrine hepatic metastases was not precluded by previous nonradioactive embolization procedures, but the effectiveness in this population requires further investigation.

Original languageEnglish (US)
Pages (from-to)145-151
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Neuroendocrine Carcinoma
Yttrium
Microspheres
Liver
Neoplasm Metastasis
Hepatic Artery
Liver Diseases
Radiation
Survival
Therapeutics
Population
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Murthy, Ravi ; Kamat, Paresh ; Nunez, Rodolfo ; Madoff, David C. ; Gupta, Sanjay ; Salem, Riad ; Yao, James C. / Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization. In: Journal of Vascular and Interventional Radiology. 2008 ; Vol. 19, No. 1. pp. 145-151.
@article{03c800eba5a74d47bc269c1ec6f24302,
title = "Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization",
abstract = "Hepatic artery radioembolization was performed in a cohort of patients with unresectable neuroendocrine hepatic metastases who exhibited hepatic progression or toxicity despite technically adequate embolization procedures without other reasonable therapeutic options. Eight patients (five men) with a median age of 55.5 years met the study criteria. Infusions of yttrium-90 resin microspheres were performed in a lobar fashion. Standard clinical, laboratory, and imaging follow-up was performed. Median hepatic parenchyma replacement by tumor was 55{\%} (range, 25{\%}-60{\%}). Twelve 90Y resin microsphere infusions were performed, and the median delivered activity was 33.25 mCi (range, 23-55 mCi). One partial response, four cases of disease stabilization, and three cases of progressive disease were noted. No cases of radiation-induced liver disease occurred. Median survival times were 14 months (range, 3-15 months) from the time of 90Y microsphere treatment and 36.5 months (range, 16-105 months) from the time of diagnosis of hepatic metastases. In this cohort, 90Y microsphere radioembolization of neuroendocrine hepatic metastases was not precluded by previous nonradioactive embolization procedures, but the effectiveness in this population requires further investigation.",
author = "Ravi Murthy and Paresh Kamat and Rodolfo Nunez and Madoff, {David C.} and Sanjay Gupta and Riad Salem and Yao, {James C.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.jvir.2007.09.006",
language = "English (US)",
volume = "19",
pages = "145--151",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "1",

}

Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization. / Murthy, Ravi; Kamat, Paresh; Nunez, Rodolfo; Madoff, David C.; Gupta, Sanjay; Salem, Riad; Yao, James C.

In: Journal of Vascular and Interventional Radiology, Vol. 19, No. 1, 01.01.2008, p. 145-151.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization

AU - Murthy, Ravi

AU - Kamat, Paresh

AU - Nunez, Rodolfo

AU - Madoff, David C.

AU - Gupta, Sanjay

AU - Salem, Riad

AU - Yao, James C.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Hepatic artery radioembolization was performed in a cohort of patients with unresectable neuroendocrine hepatic metastases who exhibited hepatic progression or toxicity despite technically adequate embolization procedures without other reasonable therapeutic options. Eight patients (five men) with a median age of 55.5 years met the study criteria. Infusions of yttrium-90 resin microspheres were performed in a lobar fashion. Standard clinical, laboratory, and imaging follow-up was performed. Median hepatic parenchyma replacement by tumor was 55% (range, 25%-60%). Twelve 90Y resin microsphere infusions were performed, and the median delivered activity was 33.25 mCi (range, 23-55 mCi). One partial response, four cases of disease stabilization, and three cases of progressive disease were noted. No cases of radiation-induced liver disease occurred. Median survival times were 14 months (range, 3-15 months) from the time of 90Y microsphere treatment and 36.5 months (range, 16-105 months) from the time of diagnosis of hepatic metastases. In this cohort, 90Y microsphere radioembolization of neuroendocrine hepatic metastases was not precluded by previous nonradioactive embolization procedures, but the effectiveness in this population requires further investigation.

AB - Hepatic artery radioembolization was performed in a cohort of patients with unresectable neuroendocrine hepatic metastases who exhibited hepatic progression or toxicity despite technically adequate embolization procedures without other reasonable therapeutic options. Eight patients (five men) with a median age of 55.5 years met the study criteria. Infusions of yttrium-90 resin microspheres were performed in a lobar fashion. Standard clinical, laboratory, and imaging follow-up was performed. Median hepatic parenchyma replacement by tumor was 55% (range, 25%-60%). Twelve 90Y resin microsphere infusions were performed, and the median delivered activity was 33.25 mCi (range, 23-55 mCi). One partial response, four cases of disease stabilization, and three cases of progressive disease were noted. No cases of radiation-induced liver disease occurred. Median survival times were 14 months (range, 3-15 months) from the time of 90Y microsphere treatment and 36.5 months (range, 16-105 months) from the time of diagnosis of hepatic metastases. In this cohort, 90Y microsphere radioembolization of neuroendocrine hepatic metastases was not precluded by previous nonradioactive embolization procedures, but the effectiveness in this population requires further investigation.

UR - http://www.scopus.com/inward/record.url?scp=37549056586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549056586&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2007.09.006

DO - 10.1016/j.jvir.2007.09.006

M3 - Article

C2 - 18192482

AN - SCOPUS:37549056586

VL - 19

SP - 145

EP - 151

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 1

ER -